|
Useful links about ATMPs
|
|
0
|
72
|
June 25, 2024
|
|
How to manage the long-term follow-up requirements for ATMPs?
|
|
1
|
18
|
May 2, 2025
|
|
Gene Therapy Trial Browser
|
|
0
|
5
|
May 2, 2025
|
|
ADVANCE 5-day Summer School on Cell and Gene Therapies
|
|
0
|
13
|
April 14, 2025
|
|
Guidebook for the development of ATMPs
|
|
0
|
36
|
January 8, 2025
|
|
FAST ATMP webinar part 3 - Market authorization, hospital exemptions, reimbursement
|
|
2
|
36
|
April 1, 2025
|
|
FAST ATMP webinar part 2 - Non-clinical development, clinical development, Regulation and legislation
|
|
2
|
45
|
April 1, 2025
|
|
FAST ATMP Webinar part 1 - Patient participation, classification of ATMPs, product development
|
|
2
|
107
|
April 1, 2025
|
|
Is there a guidance document for ATMPs during process changes or manufacturing scale-up?
|
|
1
|
29
|
March 19, 2025
|
|
Is there a format or guidance document for writing a product development plan and IMPD specifically for ATMPs
|
|
3
|
35
|
March 14, 2025
|
|
DARE-NL Annual Consortium Meeting
|
|
0
|
9
|
March 14, 2025
|
|
Online information about Gene Therapy for monogenic diseases - for patients
|
|
0
|
15
|
March 11, 2025
|
|
How can the lack of formal documentation in patient involvement activities be addressed?
|
|
4
|
78
|
March 11, 2025
|
|
Dutch ATMP summit
|
|
0
|
18
|
December 12, 2024
|
|
CAT template examples
|
|
2
|
63
|
February 14, 2025
|
|
Exploring Academic ATMP Development: Insights from Belgium & Comparisons with the Netherlands
|
|
0
|
13
|
February 14, 2025
|
|
EU HTA regulation impact and ATMP market access?
|
|
0
|
20
|
February 5, 2025
|
|
Regulatory expectations for potency assays
|
|
0
|
21
|
January 23, 2025
|
|
Patient limits for Hospital Exemption in the Netherlands
|
|
2
|
55
|
January 21, 2025
|
|
How do clinical study requirements for ATMPs differ from others?
|
|
1
|
34
|
January 15, 2025
|
|
Advanced Therapies 2025 - London
|
|
0
|
15
|
December 12, 2024
|
|
What are the current guidelines for environmental risk assessments of ATMPs, particularly those involving GMOs?
|
|
1
|
26
|
September 9, 2024
|
|
What are the current regulatory pathways for ATMPs in the EU and how do they compare with those in the US?
|
|
0
|
8
|
August 30, 2024
|
|
What can medical centres do to anticipate future ATMP therapies, how can they improve their centre readiness?
|
|
0
|
13
|
August 30, 2024
|